Lantern Pharma reports FY2022 net loss $14.3M; cash $55.2M; IND timeline for LP-184/LP-284 in 2023

Lantern Pharma Inc.

FY2022 net loss $14.3M ($1.31/sh) vs $12.4M ($1.13/sh) in FY2021; cash and equivalents $55.2M (Dec 31, 2022) down from $70.7M.
IND submission for LP-184 expected April 2023; LP-284 IND and first-in-human Phase 1 trials targeted for mid-2023.
Phase 2 Harmonic trial (LP-300) activated 5 sites across 12 US locations; first patient dosing anticipated Q2 2023.
Formed wholly-owned subsidiary Starlight Therapeutics for CNS cancers; STAR-001 clinical trials planned for late 2023/early 2024.
RADR platform surpassed 25 billion oncology datapoints; target of 50 billion in coming year; cash runway into 2025.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Lantern Pharma Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.

Period: fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 20, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31 , 2022.

View on SEC.gov

Browse all earnings releases →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-008242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.